AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

Friday’s deal with CSPC fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in ...

AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. | AstraZeneca has ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...